Medicine background
SS-31 / elamipretide
A mitochondria-targeting peptide with a specific US medical approval.
Also discussed as: Forzinity
THE RESEARCH QUESTION
What is being investigated?
Elamipretide has been studied in mitochondrial disease. The FDA granted accelerated approval to Forzinity for Barth syndrome in patients weighing at least 30 kg in September 2025.
EVIDENCE SNAPSHOT
US accelerated approval; narrow indication
Accelerated approval requires further confirmation of clinical benefit. It is not evidence for a general anti-ageing or energy treatment in healthy people.
LIMITS & SAFETY
What should you know?
US approval does not establish UK approval or validate research-labelled SS-31 products.
FOLLOW THE EVIDENCE
Sources & further reading
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.